Power to help prevent respiratory syncytial virus (RSV) disease
ACIP AND AAP RECOMMENDED¹⁻²*
View press releaseBeyfortus® (nirsevimab-alip) is the first and only long-acting antibody indicated for the prevention of RSV lower respiratory tract disease in³:
Neonates and infants born during or entering their first RSV season
Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season